Research Areas
We primarily work in the molecular biology of cancer, focusing on understanding the intricate mechanisms that drive tumor growth and progression. Through this work, we aim to identify novel biomarkers and therapeutic strategies to improve cancer treatment outcomes.
Synthetic Lethality
Synthetic lethality in cancer refers to a scenario where the simultaneous disruption of two genes leads to cell death, while the loss of either gene alone is non-lethal. This concept is particularly useful in targeting cancer cells with specific genetic mutations, exploiting vulnerabilities that arise from their unique genetic makeup. By identifying synthetic lethal gene pairs, researchers can develop therapies that selectively kill cancer cells while sparing healthy ones. We aim to identify new biomarkers that are synthetic lethal partners and unravel the molecular mechanisms behind these dependencies, paving the way for innovative cancer treatments.
.png)
.png)
Long Non-Coding RNAs
Long non-coding RNAs (lncRNAs) play crucial roles in lung cancer by regulating gene expression at multiple levels, including chromatin remodeling, transcriptional activation, and post-transcriptional processing. They act as molecular scaffolds, decoys, or guides, influencing the activity of proteins and RNA molecules critical for tumor initiation, progression, and metastasis. Dysregulated lncRNAs in lung cancer can promote oncogenesis or disrupt tumor-suppressive pathways, contributing to therapy resistance and disease progression. We aim to understand these molecular mechanisms to develop lncRNA-based biomarkers and therapeutic strategies specifically tailored to lung cancer.